Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer

N B Leighl, F A Shepherd, D Zawisza, R L Burkes, R Feld, J Waldron, A Sun, D Payne, A Bezjak, M H N Tattersall, N B Leighl, F A Shepherd, D Zawisza, R L Burkes, R Feld, J Waldron, A Sun, D Payne, A Bezjak, M H N Tattersall

Abstract

We developed a decision aid (DA) for patients with metastatic non-small cell lung cancer (NSCLC), to better inform patients of their prognosis and treatment options, and facilitate involvement in decision-making. In a pilot study, 20 patients with metastatic NSCLC attending outpatient clinics at a major cancer centre, who had already made a treatment decision, reviewed acceptability of the DA. The median age of the patients was 61 years (range 37-77 years), 35% were male, 20% had a university education, and most (75%) had English as a first language. Most had received chemotherapy, with 65% currently on treatment. Patients were not anxious at baseline and had clear understanding of the goals and toxicity of chemotherapy in advanced NSCLC. After reviewing the DA, patients' anxiety decreased slightly (P=0.04) and knowledge scores improved by 25% (P<0.001). Most improvements in understanding were of prognosis with and without chemotherapy, although patients still believed advanced NSCLC to be curable. Patients rated the DA highly with respect to information clarity, usefulness and were positive about its use in practice, although 40% found the prognostic information slightly upsetting. The DA for advanced NSCLC is feasible, acceptable to patients and improves understanding of advanced NSCLC without increasing patient anxiety.

References

    1. American Cancer Society (2006) Cancer Facts and Figures, 2006. Atlanta: American Cancer Society
    1. Barry MJ, Fowler Jr FJ, Mulley Jr AG, Henderson Jr JV, Wennberg JE (1995) Patient reactions to a program designed to facilitate patient participation in treatment decisions for benign prostatic hypertrophy. Med Care 33: 771–782
    1. Brundage M, Feldman-Stewart D, Leis A, Bezjak A, Degner L, Velji K, Zetes-Zanatta L, Tu D, Ritvo P, Pater J (2005) Communicating quality of life information to cancer patients: a study of six presentation formats. J Clin Oncol 23(28): 6949–6956
    1. Brundage MD, Feldman-Stewart D, Cosby R, Gregg R, Dixon P, Youssef Y, Davies D, Mackillop WJ (2001) Phase I study of a decision aid for patients with locally advanced non-small-cell lung cancer. J Clin Oncol 19(5): 1326–1335
    1. Cassileth BR, Zupkis RV, Sutton-Smith March V (1980) Informed consent–why are its goals imperfectly realized? N Engl J Med 302: 896–900
    1. Davidson JR, Brundage MD, Feldman-Stewart D (1999) Lung cancer treatment decisions: patients' desires for participation and information. Psychooncology 8: 511–520
    1. Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC (2004) Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22(2): 315–321
    1. Fiset V, O'Connor AM, Evans W, Graham I, Degrasse C, Logan J (2000) Development and evaluation of a decision aid for patients with stage IV non-small cell lung cancer. Health Exp 3: 125–136
    1. Gamble K (1998) Communication and information: the experience of radiotherapy patients. Eur J Cancer Care 7: 153–161
    1. Gattellari M, Butow PN, Tattersall MH, Dunn SM, MacLeod CA (1999) Misunderstanding in cancer patients: why shoot the messenger? Ann Oncol 10: 39–46
    1. Gattellari M, Voigt KJ, Butow PN, Tattersall MH (2002) When the treatment goal is not cure: are cancer patients equipped to make informed decisions? J Clin Oncol 20(2): 503–513
    1. Gelber RD, Godhirsch A, Cole BF (1993) Evaluation of effectiveness: Q-TwiST. Cancer Treatment Rev 19(Suppl A): 73–84
    1. Jadad AR, Gagliardi A (1998) Rating health information on the Internet: navigating to knowledge or to Babel? JAMA 279: 611–614
    1. Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR, Moore DF, Israel VK, Livingston RB, Gandara DR (2001) Randomized Phase II Trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group Trial. J Clin Oncol 19: 3210–3218
    1. Lobb EA, Butow PN, Kenny DT, Tattersall MH (1999) Communicating prognosis in early breast cancer: do women understand the language used? Med J Australia 171: 290–294
    1. Lopez PG, Stewart DJ, Newman TE, Evans WK (1997) Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group. Cancer Prev Control 1: 18–27
    1. Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F (1994) Chemotherapy vs. supportive care in advanced non-small cell lung cancer. Results of a meta-analysis of the literature. Chest 106: 861–865
    1. Matsuyama R, Reddy S, Smith TJ (2006) Why do patients choose chemotherapy near the end of life? A review of the perspective of those facing death from cancer. J Clin Oncol 24: 3490–3496
    1. National Cancer Institute of Canada (2006) Canadian Cancer Statistics 2006. Canadian Cancer Society/National Cancer Institute of Canada: Canadian Cancer Statistics: Toronto, Canada, April 2006, ISSN 0835–297
    1. National Health and Medical Research Council (1999) How to Present the Evidence for Consumers: Preparation of Consumer Publications. Canberra, ACT: AusInfo, Commonwealth of Australia
    1. Non-small Cell Lung Cancer Collaborative Group (2000) Chemotherapy for non-small cell lung cancer (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software.
    1. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899–909. Issue 2. Art. no.: CD002139. doi: 10.1002/14651858.CD002139
    1. O'Connor A, Tugwell P, Elmslie T, Wells G (1995) Do decision aids help postmenopausal women considering preventive hormone replacement therapy (HRT)? Med Decis Making 15: 433
    1. O'Connor AM, Rostom A, Fiset V, Tetroe J, Entwistle J, Llewellyn-Thomas H, Holmes-Rovner M, Barry M, Jones J (1999) Decision aids for patients facing health treatment or screening decisions: systematic review. BMJ 319: 731–734
    1. Paesmans M (2002) Benefits of chemotherapy for quality of life in patients with advanced nonsmall-cell lung cancer. Curr Opin Oncol 14(4): 389–393
    1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2): 92–98
    1. Sorenson S, Glimelius B, Nygren P, SBU-group. Swedish Council of Technology Assessment in Health Care (2001) A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncologica 40: 327–339
    1. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz P, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods BL, Bernard JP (1993) Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 342: 19–21
    1. Weeks JC, Cook EF, O'Day SJ, Peterson LM, Wenger N, Reding D, Harrell FE, Kussin P, Dawson NV, Connors Jr AF, Lynn J, Phillips RS (1998) Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA 279: 1709–1714
    1. Wyatt JC (1997) Commentary: measuring quality and impact of the World Wide Web. BMJ 314: 1879–1881

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa